5. 1982 : Dilip S. Shanghvi launches Sun Pharmaceutical in Calcutta. 1983 : With a loan of Rs 10,000, Sun Pharmaceutical begins manufacturing drugs, then opens its manufacturing "shed" in Vapi. 1986 : The company moves its administrative and corporate headquarters to the West Coast and extends marketing coverage across India. 1987 : The company unveils its cardiology products line. 1989 : The company launches its another products line and begins export operations.
6. 1993 : The SPARC research and development facility is opened; offices in Moscow and Toronto are opened. 1994 : The company goes public(IPO) on several Indian stock exchanges. 1996 : The company acquires Knoll Pharma's bulk actives division; it acquires stakes in Caraco (U.S.A.) and Gujarat Lyka Organics Ltd.; a stake in MJ Pharma also is acquired. 1997 : TDPL is acquired and the company reorganizes into six operating divisions. 1998 : The company acquires brands from Natco Pharma, including time-release technology. 2000 : The company acquires the Pradeep Drug company, based in the Madras region. 2002 : A new manufacturing plant opens in Dadra; the company boosts its stake in Caraco to 65 percent.
7. Selection of Location:- By the end of its first year, Sun had moved into its own manufacturing facility--spending $50,000 to install its production into a self-described "shed" of 3,000 square feet in the town of Vapi, on the country's west coast, near the pharmaceutical center of Mumbai (Bombay). Discussing the reason behind the move with Business World, Shanghvi explained: "The industry was concentrated in the western region and it was easier to get permission there to launch new drugs." Having specialists in all the therapy areas that it has a presence in. specialty product baskets that are customized to a country's needs. The learning from international markets that equip the company eventually to launch innovative products across international markets of interest.